6:07 PM
 | 
Oct 22, 2012
 |  BC Extra  |  Clinical News

Bayer's riociguat meets Phase III PAH endpoint

Bayer AG (Xetra:BAYN) said riociguat with or without endothelin receptor antagonists/non-IV prostanoids met the primary endpoint of improving six-minute walk test (6MWT) distance...

Read the full 105 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >